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Translational Relevance 
Preliminary results of the recent PACIFIC trial established clinical evidence of therapeutic 
synergy between PD-1 or PD-L1 immune checkpoint blockade and chemoradiation. PD-L1 
inhibitor durvalumab is the first consolidative therapy to reduce risk of disease progression or 
death after concurrent chemoradiation (cCRT) in patients with unresectable Stage III non-small 
cell lung cancer (NSCLC), although outcomes remain blinded to overall survival. Further efforts 
to incorporate immune checkpoint inhibitors should focus on accurate biomarker development and 
patient selection and the ideal sequence or combinations of immunotherapy and chemoradiation.  
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Abstract 
Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard of care 
therapy for patients with Stage III unresectable non-small cell lung cancer (NSCLC). Though 
potentially curative, five-year overall survival has hovered around 20%, despite extensive efforts 
to improve outcomes with increasing doses of conformal radiation and intensification of systemic 
therapy with either induction or consolidation chemotherapy. PD-1/PD-L1 immune checkpoint 
inhibitors have demonstrated unprecedented efficacy in patients with Stage IV NSCLC.  
Additionally, preclinical and early clinical evidence suggests that chemotherapy and radiation may 
work synergistically with anti-PD-1/PD-L1 therapy to promote anti-tumor immunity, which has 
led to the initiation of clinical trials testing these drugs in patients with Stage III NSCLC. A 
preliminary report of a randomized phase III trial, the PACIFIC trial, demonstrated an impressive 
increase in median progression-free survival with consolidative durvalumab, a PD-L1 inhibitor, 
compared to observation after cCRT. Here, we discuss the clinical and translational implications 
of integrating PD-1/PD-L1 inhibitors in the management of patients with unresectable Stage III 
NSCLC.  
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Concurrent Chemoradiation in Stage III NSCLC 
Concurrent chemoradiation (cCRT) became standard of care in the treatment of 
unresectable Stage III non-small cell lung cancer (NSCLC) following the RTOG-9410 study, 
which reported improved overall survival (OS) with cCRT compared to sequential 
chemoradiation (1). However, five-year OS rates have hovered around 15-20%, and distant 
failures, often in the brain, are common (2–4). Radiation dose escalation, induction 
chemotherapy, and consolidative chemotherapy have failed to improve and, at times, worsened 
outcomes. For example, dose escalation to 74 Gy from 60 Gy in the RTOG-0617 trial actually 
decreased median OS (20.3 vs. 28.7 months; p=0.004) (3). Induction carboplatin and paclitaxel 
in the CALGB-39801 study increased toxicity without survival benefit (5). Consolidative 
docetaxel (6), docetaxel and cisplatin (2), and cetuximab (3) following cCRT all failed to 
increase progression-free survival (PFS) or OS (Table 1). Gefitinib in a study population without 
selection for EGFR mutations after cCRT and docetaxel also worsened survival (7). The START 
trial assessed tecemotide following either sequential or cCRT. Although tecemotide appeared to 
increase PFS and OS in patients treated with prior cCRT (Table 1), it did not significantly 
change OS in the patients who had been treated with sequential chemoradiation or in a combined 
analysis of sequential and cCRT (p=0.0123), which has limited its generalization (8).  
 
PD-1/PD-L1 Inhibitors in Stage IV NSCLC 
PD-1/PD-L1 immune checkpoint inhibitors (ICIs) have proven effective in patients with 
metastatic or recurrent NSCLC (Table 2). Trials of second-line pembrolizumab, nivolumab, and 
atezolizumab conveyed increased OS compared to chemotherapy in patients previously treated 
with platinum-based chemotherapy for metastastic NSCLC or tyrosine-kinase inhibitors in the 
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setting of EGFR mutations or ALK translocation (Table 2) (9–12). Pembrolizumab remains the 
only PD-1 inhibitor to improve OS in the first-line setting (13,14). The KEYNOTE-024 trial 
included patients with recurrent or metastatic NSCLC and PD-L1 expression ≥50% who had not 
previously progressed on platinum-doublet chemotherapy. First-line pembrolizumab in this study 
extended PFS and OS in patients with less toxicity than chemotherapy (Table 2) (13). An 
updated analysis reported a median OS of 30 months with first-line pembrolizumab (15), 
surpassing figures historically reported from trials of cCRT in Stage III NSCLC (1,2,6–8). These 
unprecedented results open the possibility of their incorporation into definitive regimens.  
 
Rationale for PD-1/PD-L1 inhibition with Chemoradiation  
Though effective alone, the benefits of PD-1/PD-L1 blockade may be enhanced by 
chemoradiation (16–18). Mechanistically, radiation triggers antigen release by inducing tumor 
apoptosis or necroptosis and generates double-stranded DNA breaks, which then activate the 
interferon-inducing cGAS/STING pathway (19). Cellular catastrophe increases release of the 
antigen-presenting cell (APC) activators ATP and HMGB1 and translocation of calreticulin, 
promoting phagocytosis (20). Platinum-based chemotherapy can lead to immunogenic cell death 
alone, but it also sensitizes cancer to radiation-induced DNA damage and potentiates HMGB1 
and ATP release (20). After tumor cell phagocytosis, APCs migrate to lymph nodes and prime T-
cells with tumor-specific antigen (19). CD8+ T cells can then promote tumor-specific killing. 
However, PD-L1 is upregulated following irradiation (21,22) and chemotherapy (23), prompting 
T-cell apoptosis and anergy upon ligation to PD-1 and restricting the immune response (Figure 
1) (24,25). The addition of anti-PD-1/ PD-L1 blocks this interaction, facilitating synergistic anti-
tumor immunity (Figure 1) (21,22). 
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 Early clinical evidence supports this hypothesis of immunogenic synergy between 
immunotherapy and chemotherapy or radiation. A post-hoc analysis of a phase I trial of 
pembrolizumab in patients with metastatic NSCLC found increased OS in patients treated with 
prior radiation (26). In the phase II KEYNOTE-021 trial of patients with non-squamous 
metastatic or recurrent NSCLC who had not been selected based on PD-L1 expression, 
concurrent carboplatin, pemetrexed, and pembrolizumab yielded remarkably high response rates 
of 55% (27) even without selecting PD-L1 positive patients. This evidence, coupled with what 
has been a dismal prognosis, provides further rationale for PD-1/PD-L1 ICIs in Stage III 
NSCLC. 
 
Consolidative Durvalumab in Stage III NSCLC 
Preliminary results of the PACIFIC trial, a Phase III, placebo-controlled trial comparing 
the PD-L1 ICI durvalumab against observation after cCRT, were recently reported (28). 
Durvalumab increased PFS by 11 months compared to observation after cCRT, striking 
compared to results from prior trials of consolidative therapy (Table 1). Responses proved 
durable: no patients deemed partial or complete responders at 12 months progressed 6 months 
after discontinuing durvalumab. After a median follow-up of 14.5 months, durvalumab decreased 
distant failures (20% vs. 32%), including brain metastases (5.5% vs. 11%) (28). Thus, the 
systemic disease control which was previously unattainable with consolidative chemotherapy 
may be possible with durvalumab. Durvalumab was also remarkably tolerable, as it only slightly 
increased grade 3 or 4 toxicities (29.9% vs. 26.1%) and did not increase treatment-related deaths 
(4.4% vs. 5.6%) (28). Interestingly, the control arm underperformed with a PFS of just 5.6 
months. This may, at least in part, be explained by differences in the definition of PFS. Whereas 
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prior trials have measured PFS from initiation of cCRT to disease progression (3), PFS in the 
PACIFIC trial was defined as the time from randomization, which occurred up to 42 days after 
completion of cCRT, to progression. Nevertheless, this does not entirely account for a 6 month 
difference in PFS from the RTOG-0617 trial.   
Despite these robust responses, the importance of OS data from this trial cannot be 
understated, and it is unclear whether consolidative durvalumab prolongs time to relapse or truly 
increases rates of cure. Another element of uncertainty, albeit minor, is whether early 
(consolidative) or delayed (at the time of recurrence) durvalumab differentially impacts survival, 
as patients were not permitted to crossover from the observation to durvalumab arm. No trials 
have established a standard-of-care role for durvalumab in Stage IV NSCLC; however, 
pembrolizumab monotherapy would be standard of care for patients who progressed with 
observation after cCRT and whose tumors are strongly PD-L1-positive (13,29). The RTOG-3505 
trial, which evaluates consolidative nivolumab against observation after cCRT and permits 
crossover from the observation arm, may definitively answer this question (Table 3) (30).  
 
Patient Selection and Biomarkers 
Beyond the need for accurate survival data, the ability to predict the need for and benefit 
of consolidative immunotherapy would be ideal, especially given the curability of cCRT alone 
and the cost of ICIs. To date, PD-L1 expression is the only biomarker that informs clinical use of 
ICIs (29). In the metastatic setting, first-line pembrolizumab yielded response rates of 44.8% in 
patients with PD-L1 expression ≥50% (13), yet, in the CheckMate-026 trial, first-line nivolumab 
was not superior to chemotherapy with only 26% of patients with PD-L1 expression ≥5% 
responding to nivolumab (Table 2) (14). Considerable discordance has been reported between 
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each drug’s accompanying PD-L1 assay, which may distort extrapolations from one trial to 
another (31). However, PD-L1 expression was also positively correlated with increased response 
rates, PFS, and OS of second-line atezolizumab, nivolumab, and pembrolizumab (9–12). Despite 
the limitations of PD-L1 assays, these studies collectively suggest PD-L1 expression influences 
the efficacy of PD-1/PD-L1 inhibitor monotherapy.   
The PACIFIC trial did not select patients based on PD-L1 expression, and it reported that 
durvalumab reduced progression regardless of PD-L1 expression (28). It is possible that PD-L1 
expression plays less of a role in combination therapy. In KEYNOTE-021 trial, for example, 
combination carboplatin, pemetrexed, and pembrolizumab yielded response rates of 57% in 
patients with <1% PD-L1 expression vs. 54% in those with ≥1% PD-L1 expression (27). 
Nevertheless, the role of PD-L1 in patients with Stage III disease should not yet be discounted 
for several reasons. First, PD-L1 testing was not performed in over one-third of patients (28). 
Second, the trial analyzed PD-L1 as a binary variable, despite its continuous impact on outcomes 
(31). Notably, there was a trend toward decreasing risk of progression with durvalumab in 
patients with PD-L1 expression ≥25% (HR: 0.41; CI: 0.26-0.65) vs. <25% (HR: 0.59; CI: 0.43-
0.82) (28). Whether the benefit of durvalumab dissipated with lower levels of PD-L1 expression 
is unclear, although the RTOG-3505 trial, which stratifies patients according to PD-L1 
expression (<1% vs. ≥1%), may clarify this (Table 3) (30). Another issue is the variability in 
PD-L1 assay itself. The companion antibody clone (SP142) used in the PD-L1 assays of the 
PACIFIC trial has considerable inter-observer variability and detects lower levels of PD-L1 
compared to others (31), as it excludes immune cell PD-L1 expression (32). Finally, PD-L1 
testing was performed on tissue obtained prior to therapy, which would not capture increases in 
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PD-L1 expression after cCRT (16,17,21,33). While post-cCRT PD-L1 expression would be more 
reliable, tissue re-biopsy may be unfeasible.  
Other novel biomarkers have also been proposed. For example, the number of somatic 
tumor mutations positively correlates with neoantigen-specific T cell reactivity and 
pembrolizumab response (34). An exploratory analysis of the CheckMate-026 trial showed that 
tumor mutation burden is independent of and complimentary to PD-L1 expression as a 
biomarker of response (14). Patients with both high tumor mutation burden and ≥50% PD-L1 
expression had a 75% response rate to nivolumab, while patients with <50% PD-L1 expression 
and low tumor mutation burden had a response rate of just 16%. Even so, tumor mutation 
burden, like PD-L1, could theoretically be affected by cCRT. Development of a serologic 
biomarker could circumvent the need for post-cCRT re-biopsy. One candidate is the protein 
BIM, the mediator of apoptosis following PD-1 activation (35). Plasma BIM levels were 
correlated with response to PD-1 inhibitors in one early study (36). Nevertheless, these emerging 
biomarkers will need to validated in patients receiving cCRT.  
Another conundrum in patient selection, the efficacy of PD-1/PD-L1 ICIs in patients with 
targetable EGFR mutations and ALK translocations NSCLC, which are characterized by lower 
mutation burdens, is questionable (37). These patients were excluded from trials of first-line 
nivolumab and pembrolizumab in metastatic NSCLC (13,14). None of the trials of second-line 
nivolumab, pembrolizumab, or atezolizumab reported benefit in patients with ALK-translocation 
(37), and one meta-analysis reported equivalency between these agents and docetaxel in the 
EGFR-mutant subgroup (38). Independent of immunotherapy, the optimal management of 
patients with EGFR-mutant or ALK-positive Stage III NSCLC is under active investigation with 
one trial of induction targeted therapy with erlotinib or crizotinib underway (39). In the PACIFIC 
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trial, EGFR status was unknown in approximately one-fourth of patients (28). In the 6% of 
patients with known EGFR mutations, the benefit of durvalumab was unclear (HR: 0.76; CI 
0.35-1.64). Patients with ALK translocations were not excluded from this study, but no data 
specific to their outcomes were reported. Further research into both targeted therapy and 
immunotherapy in these patients is needed to determine their optimal management. 
 
Future Directions: Toward the Optimal Regimen  
The PACIFIC trial raises questions regarding the timing between cCRT and 
immunotherapy. Consolidative durvalumab reduced progression regardless of when it was 
initiated (28). However, greater reductions were observed if durvalumab was initiated within ≤2 
weeks of radiation (HR: 0.39; CI: 0.26-0.58) rather than >2 weeks after radiation (HR: 0.63 CI: 
0.49–0.80), suggesting a critical window in which to initiate PD-L1 blockade. This corroborates 
retrospective studies which identified improved outcomes in patients treated with 
immunotherapy concurrently or in close proximity to radiation (40,41). Ongoing trials of PD-
1/PD-L1 inhibitors, listed in Table 3, initiate immunotherapy at varying time points; their 
collective results may elucidate the ideal interval between cCRT and consolidative 
immunotherapy. 
In terms of improving upon the results of the PACIFIC trial, perhaps the efficacy of 
immunotherapy after cCRT could be augmented with additional consolidative therapy. Given the 
potential for chemotherapy to synergize with PD-1/PD-L1 ICIs as demonstrated by the 
KEYNOTE-021 study, it is possible that adding platinum-doublet chemotherapy to consolidative 
immunotherapy could improve responses (27). Another prospect is dual immune checkpoint 
inhibition with a PD-1/PD-L1 ICI and the CTLA4 ICI ipilimumab, a regimen with high response 
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rates in an early trial of patients with Stage IV NSCLC (42). One ongoing study, NCT03285321 
(43), is currently studying this approach in patients with Stage III NSCLC using the combination 
of nivolumab and ipilimumab after cCRT (Table 3).  
The impact of durvalumab on local disease control may also reveal a role for PD-1/PD-
L1 ICIs as induction or concurrent (during cCRT) therapy. Suboptimal locoregional control has 
remained a challenge after cCRT with 5-year in-radiation field recurrence rates of 25%-29% (1). 
Though radiation dose escalation may improve locoregional control (44), its toxicity to normal 
heart and lung tissue remains a limiting factor (3). Induction systemic therapy could theoretically 
improve both systemic and local control by treating systemic microscopic systemic disease early 
and reducing tumor volumes to allow for radiation fields more amenable to dose escalation. 
However, such an approach has historically been limited by poor responses to chemotherapy 
(44). Data from the PACIFIC trial suggest that PD-1/PD-L1 ICIs could fill this role, as 
consolidative durvalumab significantly increased intra-thoracic responses (28.4% vs. 16%; 
p<0.001) (28). One Phase II trial (NCT03102242) testing a regimen of cCRT preceded and 
followed by induction and adjuvant atezolizumab will help to characterize responses to induction 
immunotherapy in patients with Stage III NSCLC (Table 3) (45).  
 Another investigational strategy to safely increase radiation doses is dose adaptation 
during cCRT. In the RTOG-1106 trial, for example, patients are re-simulated with PET-CT after 
the first 21 fractions of cCRT (46). Should interval reductions in tumor volumes allow for dose 
escalation, primary tumors are then treated to 80.4 Gy. Given the impact of durvalumab on 
intrathoracic disease, perhaps concurrent tri-modality therapy (PD-1/PD-L1 ICIs and 
chemoradiation) could better facilitate dose adaptation and escalation. Two early trials, 
NCT02434081 and NCT02621398,  are testing nivolumab (47) or pembrolizumab (48), 
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respectively, given concurrently and adjuvantly with respect to cCRT (Table 3) .These trials 
may determine not just whether concurrent tri-modality therapy is tolerable enough to justify 
dose adaptation, but also whether anti-tumor activity is potentiated with this approach.  
 In conclusion, preliminary data support the potential of ICIs after cCRT to improve both 
local and systemic disease control of unresectable Stage III NSCLC, although we cautiously 
await reports of OS from the PACIFIC trial and others. Future research into the development of 
accurate biomarkers, such as PD-L1 expression and tumor mutation burden, and into the optimal 
timing between chemoradiation and immunotherapy will be critical. The PACIFIC trial raises 
even more therapeutic possibilities, including induction immunotherapy, radiation dose 
adaptation, and combination consolidative therapy. Regardless, it represents a step toward finally 
improving the dismal prognosis of locally advanced NSCLC after nearly two decades of efforts.   
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Table 1. Multi-institutional Phase III Trials of Consolidative or Induction Systemic Therapy 
after concurrent chemoradiation for unresectable Stage III NSCLC.  
 
 
Trial Induction or Consolidative 
Therapy with cCRT 
PFS  
(months) 
(P-value) 
 
OS 
(months)  
(P-value) 
CALGB-39801 
(5) 
Carboplatin + Paclitaxel 
(induction) 
7 vs. 8 (NS) 12 vs. 14 (NS) 
HOG LU-0124 
(6) 
Docetaxel 
(consolidation) 
10.8 vs. 10.3 (NS) 
 
24.2 vs. 26.1 (NS) 
Korean Cancer 
Study Group - 
LU05-04 (2) 
Cisplatin 
+ 
Docetaxel 
(consolidation) 
9.1 vs. 8.1 (NS) 21.8 vs. 21.6 (NS) 
RTOG-0617 
(3)* 
Cetuximab 
(consolidation) 
10.8 vs. 10.7 (NS) 
 
25 vs. 24 (NS) 
SWOG-S0023 
(7) 
Docetaxel followed by 
Gefitinib 
(consolidation) 
8.3 vs. 11.7 (NS) 23 vs. 35 (p = 0.013) 
START (8)** Tecemotide 
(consolidation) 
14.2 vs. 11.4  
(p=0.02) 
30.8 vs. 20.6 (p=0.016) 
PACIFIC (28) Durvalumab 
(consolidation) 
16.8 vs. 5.6 
(p<0.0001) 
Ongoing 
PFS: Progression-free survival OS: Overall Survival NS: Not statistically significant. All values 
from clinical trials are presented as experimental arm value vs. control arm value.  
*Data are shown regardless of irradiation to 60 Gy or 74 Gy. 
**Data from patients who received prior concurrent chemoradiation are shown.  
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Table 2. Phase III Trials of PD-1/PD-L1 Inhibitors in Patients with Metastatic or Recurrent 
NSCLC 
 
Trial Hist. PD-L1 
Exp. 
Experimental 
vs. Control 
Arms 
 
1st  
or 2nd 
Line 
Therapy 
PFS  
(months) 
(P-value) 
OS 
(months) 
(P-value) 
KEYNOTE-010 
(10)* 
Any ≥1% Pembrolizumab 
(2mg/kg or 
10mg/kg, 
respectively) 
vs. Docetaxel 
Second 
Line  
3.9 and 4.0 
vs. 4.0 
(NS, NS) 
10.4 and 
12.7 vs. 8.5 
(p=0.008, 
p<0.001) 
CheckMate-017 
(12) 
Squamous Any Nivolumab vs. 
Docetaxel 
Second 
Line  
3.5 vs. 2.8  
(p<0.001) 
9.2 vs. 6.0  
 (p<0.001) 
CheckMate-057 
(11) 
Non-
squamous 
Any Nivolumab vs. 
Docetaxel 
Second 
Line  
2.3 vs. 4.2 
(NS) 
12.2 vs. 9.5 
 (p=0.002) 
OAK  
(9) 
Any Any Atezolizumab 
vs. Docetaxel 
Second 
Line 
2.8 vs. 4.0  
(NS) 
13.8 vs. 9.6  
(p=0.003) 
KEYNOTE-024 
 (13) 
Any ≥50% Pembrolizumab 
vs. 
Investigators’ 
Choice 
Chemotherapy 
First  
Line  
10.3 vs. 6.0 
(p<0.001) 
 
30.0 vs. 
14.2 
(p=0.002) 
CheckMate-026 
 (14) 
Any ≥5%  Nivolumab vs. 
Investigators’ 
Choice 
Chemotherapy  
First 
 Line  
4.2 vs. 5.9 
(NS) 
14.2 vs. 
13.2 (NS) 
Hist: Histology; Exp: Expression PFS: Progression-free survival OS: Overall Survival NS: 
Not statistically significant. 
All values from clinical trials are presented as experimental arm value vs. control arm value. 
*Survival data are reported as follows: pembrolizumab (2mg/kg) and pembrolizumab 
(10mg/kg) vs. docetaxel. P-values are reported as: (pembrolizumab (2mg/kg) vs docetaxel; 
pembrolizumab (10mg/kg) vs docetaxel) 
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Table 3. Ongoing Studies Incorporating PD-1/PD-L1 ICIs into cCRT regimens in the Treatment 
of Stage III NSCLC  
Study Phase Study Arm(s) Timing of Immunotherapy 
Initiation 
RTOG-3505 
(30) 
III Nivolumab vs. Observation 4-12 weeks after cCRT 
completion 
NCT03285321 
(43) 
II Nivolumab + Ipilimumab vs. 
Nivolumab alone 
28-56 days after cCRT 
completion 
NCT03102242 
(45) 
II Atezolizumab (induction and 
adjuvant) 
Induction: 2 or 4 3-week cycles 
Adjuvant: 3-5 weeks after cCRT 
completion 
NCT02434081 
(47) 
II Nivolumab (concurrent and 
adjuvant) 
Within 30 days of first cycle of 
chemotherapy 
NCT02621398 
(48) 
I Pembrolizumab (concurrent 
and adjuvant) 
 
Same day as cCRT initiated 
cCRT: Concurrent chemoradiation therapy 
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Figure Legend 
Figure 1. Immunogenic Synergy between Chemoradiation and PD-L1 Inhibitors.  
Chemoradiation increases tumor antigen release, and induces DNA-breaks, which increase ATP, 
HMGB1, interferons (INF), and translation of calreticulin (CRT). Collectively, this activates 
APCs, which migrate to the lymph nodes and prime CD8+ T cells with tumor antigen. The 
addition of PD-1/PD-L1 blockade inhibits T cell exhaustion, facilitating anti-tumor immunity.  
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